11.04.2019 – 09:00 Debiopharm International SAGenePOC obtains CE marked for its GenePOC(TM) Carba test Québec, Canada (ots) - GenePOC Inc., member of the Debiopharm Group, announces its third test to be CE marked, the GenePOC Carba assay, to be used with the revogene(TM) device. About carbapenem-producing organisms (CPO) CPO are considered a serious global public health threat and are associated with significant morbidity, mortality and hospital costs¹. In 2015, 13 of the 38 countries of the European Union and European ... more
21.03.2019 – 14:00 Debiopharm International SAGenePOC obtains FDA clearance for its GenePOC(TM) Strep A test in the US Québec, Canada (ots) - GenePOC Inc., member of the Debiopharm Group, announces its third test to be cleared by the FDA, the GenePOC Strep A assay, to be used with the revogene(TM) device. About Group A Streptococcus (GAS) infection GAS is the most common bacterial etiology of pharyngitis accounting for 15 to 30% cases in children and 5 to 20% in adults[1]. In the ... more
26.02.2019 – 09:00 Debiopharm International SADebiopharm International SA Initiates a Clinical Trial Phase II study evaluating afabicin in Bone and Joint Infections Lausanne, Switzerland (ots) - Debiopharm International SA (Debiopharm - www.debiopharm.com/debiopharm-international/), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate its antibiotic afabicin (Debio 1450) ( ... more
23.10.2018 – 14:00 Debiopharm International SAGenePOC® launches its GenePOC® CDiff test in Canada Québec, Canada (ots) - GenePOC announces the Health Canada approval and launch of its molecular diagnostic test for the detection of Clostridium difficile in Canada GenePOC Inc., member of the Debiopharm Group, is proud to announce the approval by Health Canada and the launch of its GenePOC CDiff assay to be used with the revogene(TM) instrument. About the Clostridium difficile infection (CDI) In Canada, CDI is the main ... more
